• SELECT SITE CURRENCY
Select a currency for use throughout the site
OctoPlus N.V. - Product Pipeline Review - Q4 2010
Global Markets Direct, December 2010, Pages: 41
OctoPlus N.V. – Product Pipeline Review – Q4 2010
Global Market Direct’s pharmaceuticals report, “OctoPlus N.V. - Product Pipeline Review - Q4 2010” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.
- OctoPlus N.V. - Brief company overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of OctoPlus N.V. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of OctoPlus N.V. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the OctoPlus N.V.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.
Reasons to buy
- Evaluate OctoPlus N.V.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of OctoPlus N.V. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the OctoPlus N.V.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with OctoPlus N.V..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of OctoPlus N.V. and identify potential opportunities in those areas.
List of Tables
List of Figures
OctoPlus N.V. Snapshot
OctoPlus N.V. Overview
OctoPlus N.V. – Research and Development Overview
Key Therapeutic Areas
OctoPlus N.V. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
OctoPlus N.V. – Pipeline Products Glance
OctoPlus N.V. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
OctoPlus N.V.–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
OctoPlus N.V. – Drug Profiles
Mechanism of Action
Mechanism of Action
Mechanism of Action
OctoPlus N.V. – Pipeline Analysis
OctoPlus N.V. – Pipeline Products by Therapeutic Class
OctoPlus N.V. Pipeline Products By Target
OctoPlus N.V. – Pipeline Products by Route of Administration
OctoPlus N.V. – Pipeline Products by Molecule Type
OctoPlus N.V. – Locations And Subsidiaries
Other Locations & Subsidiaries
Sep 26, 2007: OctoPlus In-Licenses Diabetes Product Candidate
Mar 23, 2005: Theratechnologies Announces Phase I Trial Results For TH0318
Financial Deals Landscape
OctoPlus N.V., Deals Volume Summary, 2004 to YTD 2010
OctoPlus N.V., Deals Summary By Region, 2004 to YTD 2010
OctoPlus N.V., Deals Summary, 2004 to YTD 2010
OctoPlus N.V. Detailed Deal Summary
OctoPlus Secures $23.74 Million In Second Round Of Financing
OctoPlus Secures $2.61 Million In First Round Of Financing
OctoPlus Completes Private Placement Of Shares For $5.76 Million
OctoPlus Completes Private Placement Of $7.55 Million
Biolex Enters Into Collaboration With Octoplus
SurModics Enters Into Licensing Agreement With OctoPlus
Biolex Therapeutics Enters Into Agreement With Octoplus
Theratechnologies Enters Into Licensing Agreement With OctoPlus
Expert Panel Validation